Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$13.07
▼ $0.54 (-4.0%)
Market data updated: 09/16 08:22 AM
Fundamentals updated: 09/16/2026
News analyzed: 09/16/2026
Market Cap
$1.29B
Day Range
$12.88 - $13.58
52-Week Range
$12.88 - $39.89
Beta
—
Next Earnings
02.11.2026
RARE is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
-54.9% (1Y)
Strengths: 5/30 factors positiveRisk: High
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🔴 Bearish
Technical Trend
🔴 Bearish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Revenue growth (last year)
Revenue growth (last year): 20.2%
Growth
Biggest negative driver
DCF Fair Value
Estimated fair value: -$117.07 vs. price $13.07 (-995.7%)
Fair Value
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 1 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 1
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
31
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
48
Quality
58
Value
38
Momentum
9
Risk
34
Sentiment
20
Fundamental
31
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Ultragenyx Pharmaceutical Inc. has centered on a **major clinical setback**—the failure of its Phase 3 Aspire trial for apazunersen in Angelman syndrome, which led to a **40% stock drop** and a review of the program. Analysts downgraded the stock, slashing price targets by up to **76%**, while the company announced **cost-cutting measures**. Despite a rare pediatric disease approval for GENGLYCOS, the broader market reaction reflected skepticism, with shares falling to **52-week lows** amid investor concerns over pipeline risks and valuation.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Ultragenyx Pharmaceutical Inc.. News trend score: 20. Reason: 9 of the last 20 articles are negative, versus 4 positive.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
50
🎯 Conviction (vs. Emotion)
41
Psychology
82
Fundamentals
31
Technical
9
Valuation
38
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
A significant decline over time, but on unusually low trading volume — holders unwilling to accept the loss.
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
Price (3M)
-51%
Market Narrative
21
Fundamental Reality
41
Narrative Gap
-20
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
The market’s extreme volume (2.49x) and oversold RSI (21) dominate, signaling panic selling despite a narrative-reality gap (-21). Loss aversion (41) coexists but is secondary, as traders likely liquidate to cut losses rather than hold for recovery. The key question is whether the selling is exhaustion-driven or a continuation of distress. Herding is minimal, suggesting targeted selling rather than contagion. The absence of euphoria or overconfidence reinforces a purely bearish, risk-off environment.
Updated: 09/09/2026, 09:26 AM
What could change this?
👥 What the crowd believes
"its Phase 3 Aspire trial of apazunersen (GTX-102) in Angelman syndrome failed to meet its primary and key secondary cognitive and functional endpoints"
"Wall Street removed the Angelman program from valuation models, slashing price targets by as much as 76%"
"RARE Stock Crashes In Worst Day Ever"
"current market multiples still screen as expensive and the broader valuation checks send a mixed message"
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Charles Mackay — 100/100
🔴 Weakest match
Morgan Housel — 0/100
🗣️ Why do they disagree?
This stock’s starkly divided verdicts reflect deep methodological clashes between cyclical, fundamental, and behavioral frameworks. The highest-scoring approaches—Mackay’s crowd psychology, Nelson’s cycle analysis, and Marks’ market-cycle view—all suggest RARE sits in a favorable position, either because it lacks speculative frenzy or aligns with early-to-mid cycle dynamics. Meanwhile, Graham’s valuation constraints and Fisher’s quality standards pull back, doubting whether the stock’s fundamentals or growth narrative justify its price. Behavioral investors like Loeb and Housel see red flags: Loeb flags excessive risk, while Housel’s volatility score implies it could erode patience. Even Livermore’s low score underscores a potential trend mismatch, while Veblen’s critique hints at speculative overreach. The divide isn’t just about optimism vs. caution—it’s about whether RARE’s profile fits *mechanical* rules (cycle positioning) or *qualitative* thresholds (Fisher’s patience, Graham’s margin of safety).
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 100
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟢 100
Looks early-to-mid cycle, not overextended
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 98
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟢 74
A real, disciplined setup with favorable reward/risk
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 60
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🟡 59
Adequate but not exceptional liquidity
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟡 48
Reasonable but not a clear long-term holding
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟡 45
Mixed — growth exists but the price already reflects much of it
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 44
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 43
Doesn't show the quality/growth signature Fisher required
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🔴 32
Weak case — Malkiel/Bogle would say a low-cost index is the simpler bet
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🔴 30
Fails most of Graham's defensive criteria
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🔴 29
Risk profile Loeb would flag as a real threat to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🔴 22
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🔴 21
Pattern Veblen would flag as growth pursued for its own sake
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 0
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Based on the last 277 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (0 bullish · 10 bearish · 1 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear downtrend with no defined trading range in the period examined.
Medium confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
83.8%
Operating Margin
-79.5%
Net Margin
-85.4%
EBITDA Margin
—
ROE
-222.9%
ROA
-37.5%
ROIC
—
EPS
-$5.83
Cash
$421.00M
Total Debt
—
Current Ratio
2.48
Debt/Equity
3.41
How is Fair Value calculated? →
Current Price
$13.07
Estimated Fair Value (DCF)
-$117.07
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
-995.7%
🔴 Appears expensive relative to estimated value
Year 1 Growth Rate
22.9%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 22.9% | $-580.03M | $-532.14M |
| 2 | 17.8% | $-683.22M | $-575.05M |
| 3 | 12.7% | $-769.94M | $-594.54M |
| 4 | 7.6% | $-828.43M | $-586.88M |
| 5 | 2.5% | $-849.14M | $-551.89M |
Base FCF (last actual year)
$-472.00M
Terminal Value
$-13.39B
Present Value of Terminal Value
$-8.70B
Enterprise Value
$-11.54B
Net Debt
$0
Equity Value
$-11.54B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$2.76
Tangible Book Value per Share (Tangible NAV)
$0.83
Sentiment based on basic keywords (not AI) — 4 positive, 7 neutral, 9 negative out of the last 20 articles.
Yahoo · 16.9.2026
Yahoo · 5.9.2026
Simply Wall St. · 5.9.2026
Yahoo · 5.9.2026
Simply Wall St. · 5.9.2026
Benzinga · 4.9.2026
Benzinga · 4.9.2026
Benzinga · 4.9.2026
Yahoo · 4.9.2026
Stocktwits · 4.9.2026
Yahoo · 4.9.2026
Stocktwits · 4.9.2026
Yahoo · 3.9.2026
Stocktwits · 3.9.2026
The Wall Street Journal · 3.9.2026
Yahoo · 3.9.2026
Investor's Business Daily · 3.9.2026
Yahoo · 3.9.2026
Barrons.com · 3.9.2026
MT Newswires · 3.9.2026
Ultragenyx Pharmaceutical Inc. (RARE) currently has a StockIQ AI score of 31/100, rated "Weak". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
RARE currently scores 31/100 (Weak) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, RARE's estimated fair value is -$117.07, which is 995.7% below the current price of $13.07. This is one valuation model among several signals in the fair-value category, not a price target.
RARE's technical score is 9/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Revenue growth (last year): 20.2%; Operating margin is stable or improving over time; Current ratio: 2.48.
Based on the real signals StockIQ computed: Estimated fair value: -$117.07 vs. price $13.07 (-995.7%); Operating margin: -79.5% (negative); Net margin: -85.4% (negative).
StockIQ has no recorded dividend payment history for RARE.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 15 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Huizenga Theodore Alan | Open Market Sale | 3.9.2026 | 161 | -161 | $13.99 |
| Parschauer Karah Herdman | Open Market Sale | 3.8.2026 | 1,900 | -1,900 | $24.92 |
| Horn Howard | Open Market Sale | 3.8.2026 | 4,696 | -4,696 | $24.92 |
| Horn Howard | Open Market Sale | 3.8.2026 | 96,295 | -4,696 | $24.92 |
| Parschauer Karah Herdman | Open Market Sale | 3.8.2026 | 92,562 | -1,900 | $24.92 |
| Horn Howard | Open Market Sale | 1.7.2026 | 4,698 | -4,698 | $33.13 |
| Horn Howard | Open Market Sale | 1.7.2026 | 100,991 | -4,698 | $33.13 |
| Sanders Corazon (Corsee) D. | Open Market Sale | 15.6.2026 | 2,000 | -2,000 | $25.05 |
| Parschauer Karah Herdman | Open Market Sale | 15.6.2026 | 1,899 | -1,899 | $24.62 |
| Parschauer Karah Herdman | Open Market Sale | 15.6.2026 | 94,462 | -1,899 | $24.62 |
| Sanders Corazon (Corsee) D. | Open Market Sale | 15.6.2026 | 21,095 | -2,000 | $25.05 |
| Horn Howard | Open Market Sale | 1.6.2026 | 4,653 | -4,653 | $23.77 |
| Horn Howard | Open Market Sale | 1.6.2026 | 105,689 | -4,653 | $23.77 |
| SULIMAN SHEHNAAZ | Open Market Sale | 18.5.2026 | 5,740 | -5,740 | $25.12 |
| SULIMAN SHEHNAAZ | Open Market Sale | 18.5.2026 | 27,951 | -5,740 | $25.12 |
| Dunsire Deborah | Grant/Award from Employer | 14.5.2026 | 7,751 | +7,751 | — |
| NARACHI MICHAEL | Grant/Award from Employer | 14.5.2026 | 14,058 | +14,058 | — |
| Ray Amrit | Grant/Award from Employer | 14.5.2026 | 14,058 | +14,058 | — |
| WELCH DANIEL G | Grant/Award from Employer | 14.5.2026 | 14,058 | +14,058 | — |
| WELCH DANIEL G | Grant/Award from Employer | 14.5.2026 | 7,751 | +7,751 | — |
| Dunsire Deborah | Grant/Award from Employer | 14.5.2026 | 14,058 | +14,058 | — |
| NARACHI MICHAEL | Grant/Award from Employer | 14.5.2026 | 7,751 | +7,751 | — |
| Sanders Corazon (Corsee) D. | Grant/Award from Employer | 14.5.2026 | 14,058 | +14,058 | — |
| Sanders Corazon (Corsee) D. | Grant/Award from Employer | 14.5.2026 | 7,751 | +7,751 | — |
| SULIMAN SHEHNAAZ | Grant/Award from Employer | 14.5.2026 | 7,751 | +7,751 | — |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
17,144,354 shares short as of 2026-08-31 · vs. 14,963,396 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
43.5% of trading volume this week was short selling, vs. 42.1% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology